Understand the source comparison
SS-LUP-332 Biomarkers: Clinical Use Comparison
Complement C3 90–180 mg/dL <70 mg/dL 14–21 days Moderate (60–70%) Renal flare prediction; nephritis monitoring Complement C4 10–40 mg/dL <10 mg/dL 10–18 days Early cascade activation; combined with C3 Anti-dsDNA (ELISA) <30 IU/mL >100 IU/mL 21–28 days High (95
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Complement C3
- 90–180 mg/dL
- <70 mg/dL
- 14–21 days
- Moderate (60–70%)
- Renal flare prediction; nephritis monitoring
- Complement C4
- 10–40 mg/dL
- <10 mg/dL
- 10–18 days
- Early cascade activation; combined with C3
- Anti-dsDNA (ELISA)
- <30 IU/mL
- >100 IU/mL
- 21–28 days
- High (95–98%)
- Diagnosis confirmation; renal involvement risk
- Interferon-α
- <5 pg/mL
- >10 pg/mL
- 28–35 days
- Moderate (60–80%)
- Treatment resistance prediction; photosensitivity
- IL-6
- Variable
- Low (non-specific)
- Tocilizumab response prediction
- Professional Assessment
- .
- Complement depletion and anti-dsDNA titre are the core SS-LUP-332 markers; cytokines add predictive value but are not yet standard. Combined C3/C4 depletion with rising anti-dsDNA is 91% specific for impending flare.